β‐amyloid (Aβ) is widely accepted to be one of the major pathomechanisms underlying
Alzheimer's disease (AD), although there is presently lively debate regarding the relative …

Alzheimer disease is the most prevalent form of dementia globally and is characterized
premortem by a gradual memory loss and deterioration of higher cognitive functions and …

The neurotransmitter glutamate activates several classes of metabotropic receptor and three
major types of ionotropic receptor–α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid …

Experimental models that faithfully mimic the developmental pathology of sporadic
Alzheimer's disease (sAD) in humans are important for testing the novel therapeutic …

In Alzheimer's disease (AD) basic research and drug discovery, mouse models are essential
resources for uncovering biological mechanisms, validating molecular targets and screening …

Early therapeutic interventions are essential to prevent Alzheimer Disease (AD). The
association of several inflammation-related genetic markers with AD and the early activation …

Memantine is an N-methyl-d-aspartate receptor antagonist that is approved for the treatment
of moderate to severe Alzheimer's disease (AD). In this study, three groups of triple …

Recent advances in the understanding of the pathophysiological mechanisms underlying
Alzheimer's disease have pointed to novel strategies for drug development. Animal models …

Memantine received marketing authorization from the European Agency for the Evaluation
of Medicinal Products (EMEA) for the treatment of moderately severe to severe Alzheimer's …

In addition to its definitive pathological characteristics, neuritic plaques and neurofibrillary
tangles, Alzheimer's disease (AD) brain exhibits regionally variable neuronal loss and …